loading page

Call to Action: Harmonisation of Pharmacovigilance Regulations for Post-marketing Pregnancy and Breastfeeding Safety Studies
  • +7
  • Amalia Alexe,
  • Osa Eisele,
  • Maria Fernanda Scantamburlo Fernandes,
  • David Lewis,
  • Nadezda Abramova,
  • Leesha Balramsingh-Harry,
  • Anju Garg,
  • Birgit Kovacs,
  • Keele Wurst,
  • Yenlik Zheteyeva
Amalia Alexe
Advanced Accelerator Applications SA

Corresponding Author:[email protected]

Author Profile
Osa Eisele
Author Profile
Maria Fernanda Scantamburlo Fernandes
Eli Lilly and Company
Author Profile
David Lewis
Novartis Pharma AG
Author Profile
Nadezda Abramova
Merck Group
Author Profile
Leesha Balramsingh-Harry
Author Profile
Anju Garg
Sanofi Genzyme
Author Profile
Birgit Kovacs
Boehringer Ingelheim Corp USA
Author Profile
Keele Wurst
GlaxoSmithKline USA
Author Profile
Yenlik Zheteyeva
Merck Pharmaceuticals
Author Profile


Globally, more than 200 million women become pregnant each year, most of whom receive medications despite limited information on their safe use during pregnancy. The paucity of drug safety data on pregnant and breastfeeding women stems from the routine exclusion of this population from clinical trials due to scientific, ethical, regulatory and legal concerns. Consequently, at the time of initial drug approval, there may be scant safety data to inform the drug benefit-risk balance to the mother, foetus, or infant. Although momentum is growing to include this underrepresented population in clinical trials, most information on drug exposure outcomes comes from data collected in the post-marketing setting. Regulatory guidance and legislation on medication use in pregnancy and breastfeeding were reviewed globally by TransCelerate IGR PV Pregnancy and Breastfeeding Team. ICH standards and CIOMS guidelines served as benchmarks for national safety regulations and guidance. The landscape assessment identified a lack of harmonisation of global regulations on research in pregnant and breastfeeding women. This editorial focuses on the ambiguities and lack of harmonisation in global regulations on post-marketing pregnancy and breastfeeding safety studies. There is currently no ICH standard to guide these types of safety studies and, in most regions reviewed, there are no clear regulations or guidance on when and how to conduct them. While a challenging undertaking, greater clarity and harmonisation would facilitate more timely completion of post-marketing pregnancy safety studies that would ultimately generate the critical data needed to optimize benefit-risk decisions for pregnant and breastfeeding women.
07 Dec 2022Submitted to British Journal of Clinical Pharmacology
09 Dec 2022Submission Checks Completed
09 Dec 2022Assigned to Editor
09 Dec 2022Review(s) Completed, Editorial Evaluation Pending
04 Jun 2023Reviewer(s) Assigned
13 Jul 2023Editorial Decision: Revise Minor
11 Aug 20231st Revision Received
18 Sep 2023Submission Checks Completed
18 Sep 2023Assigned to Editor
18 Sep 2023Review(s) Completed, Editorial Evaluation Pending
19 Sep 2023Editorial Decision: Accept